Approval · Notice of Compliance 23336 · 2020
BEOVU: Notice of Compliance 23336
Issued March 12, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 23336
- Date
- March 12, 2020
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
Products in this notice
Medicinal ingredients
- BROLUCIZUMAB 6 MG per UNIT